InflaRx and Staidson initiate FDA discussions for clinical trials
What happened
InflaRx and Staidson BioPharmaceuticals are initiating discussions with the FDA and starting joint clinical trials. InflaRx plans two Phase 2 trials in 2027 for ANCA-associated vasculitis (AAV), including a placebo-controlled study for renal involvement and an open-label study to replace corticosteroids. Initial data from an atypical hemolytic uremic syndrome (aHUS) pilot study is anticipated in the second half of 2027.
From manilatimes.net
Why it matters
InflaRx proprietary research indicates that izicopan could support significant AAV market expansion, with estimated peak sales potential ranging from $1.5 billion to $2.0 billion. Additionally, a Phase 3 trial for BDB-001 is underway in China, with data expected in the second half of 2028.
From manilatimes.net
Who's involved
- FDARegulatory agency InflaRx is seeking discussions with regarding clinical trials
- United States of AmericaCountry whose government provides the regulatory authority for the FDA
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- New drug trials may require DEA oversight of investigational substancesNew clinical trials for izicopan may trigger DEA oversight of investigational drugs.Possible
- InflaRx's biologic trial data may require CBER reviewInflaRx's biologic trial data may require CBER reviewPossible
- The Department of Health & Human Services oversees the regulatory path for InflaRx's new drug trialsThe Department of Health & Human Services oversees the regulatory path for InflaRx's new drug trials.Possible
- InflaRx's drug trials require CDER's regulatory evaluationInflaRx's drug trials require CDER's regulatory evaluationPossible
Keep exploring
The entities involved
Related events
- Argenx SE announced it is listed on Nasdaq and is seeking FDA priority review and approval.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- The FDA requested additional clinical data from Unicycive Therapeutics.
- FDA granted accelerated approval for VOCERYQ, causing INOVIO stock to lead Nasdaq gainers.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.